心通醫療-B(02160.HK)預期2024年淨虧損同比收窄約87%至94%
格隆匯3月6日丨心通醫療-B(02160.HK)公告,根據對集團截至2024年12月31日止年度未經審覈管理賬目的初步審閱及對董事會目前可得最新資料的評估,集團預期報告期錄得淨虧損約人民幣3000萬元至人民幣6000萬元,較截至2023年12月31日止年度減少約87%至94%。該等減少主要是由於:
1)公司的經導管主動脈瓣膜植入術產品Vita Flow®及VitaFlow Liberty®和AnchorMan®左心耳封堵器系統及其導引系統在中國的商業化有序推進,植入量持續增長;
2)公司的VitaFlow Liberty®經導管主動脈瓣膜及可回收輸送系統於報告期內獲得CE標誌,並已在海外17個國家╱地區實現銷售,來自海外的收入較2023年度增長一倍以上;
3)集團以財務報表的健康度爲重,聚焦業務,進一步開展降本控費,通過持續優化製造工藝,提升生產效率,多渠道開發材料供方及提高關鍵物料的利用率等措施降低產品成本;同時,統籌內外部資源、發揮集約效應,通過評估運營費用的投入產出,持續提高運營效率,實現業務的健康可持續增長;
4)基於集團聯營公司4C Medical Technologies,Inc.於2025年3月完成的D輪融資,並結合其最新的研發項目進展,對持有的4C Medical的股權投資,集團轉回了前期計提的減值準備;另外,對持有的4C Medical發行的可轉換債券,集團確認了公允價值變動收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.